Middle East and Africa Biosimilars Market: Industry Trends and Forecasts - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players

Description

Middle East and Africa Biosimilars Market: Overview

As per Roots Analysis, the Middle East and Africa biosimilars market is estimated to grow from USD 1,159 million in the current year to USD 5,738 million by 2035 at a CAGR of 19% during the forecast period, till 2035.

Middle East and Africa Biosimilars Market - IMG1

Middle East and Africa Biosimilars Market: Growth and Trends

The biosimilars market is expected to grow significantly in the upcoming years as patents of biologics expire, paving the way for the introduction of biosimilars that closely mimic their original counterparts. Lately, the biologics sector has experienced considerable expansion, largely due to its increased effectiveness in managing chronic diseases. Nonetheless, the high costs associated with biologics create major financial and healthcare obstacles. As the demand for biologics continues to increase, developers are exploring innovative approaches to create more affordable biologic products that maintain comparable safety and efficacy standards to optimize their investment returns.

The biosimilars market in the Middle East and Africa is currently experiencing rapid growth, fueled by increased healthcare investments, a rising prevalence of chronic diseases such as diabetes and cancer, and favorable regulatory environments in prominent countries like Saudi Arabia, the UAE, and South Africa. Particularly in areas with limited resources, the pressing demands created by chronic illnesses like diabetes and cancer necessitate the use of biologics, yet their high costs often leave many patients unable to access them. Biosimilars provide a solution by offering comparable efficacy at significantly lower prices, reducing financial strain on public health systems. In response, governments across the region are actively encouraging their adoption through tenders and incentives to enhance accessibility. This combination of necessity and affordability drives market expansion throughout MEA countries.

Growth Drivers: Strategic Enablers of Market Expansion

The Middle East and Africa Biosimilars Market experiences robust growth driven by several key factors, including rising prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders and increased demand for affordable biologic alternatives. In addition, government initiatives such as streamlined regulatory pathways for biologics also propel market growth. Further, patent expiries of major drugs like Herceptin and Rituxan, enable local manufacturers to expand portfolios rapidly. Strategic partnerships with global firms, low-cost manufacturing capabilities, and a skilled workforce further position Middle East as one of the leading exporters.

Market Challenges: Critical Barriers Impeding Progress

Challenges persist in the Middle East and Africa Biosimilars Market despite the ongoing market growth, hindering faster adoption. High development costs, complex manufacturing processes requiring stringent quality controls, and risks of immunogenicity or structural variability raise entry barriers for smaller players in this market space. Further, regulatory hurdles, including evolving guidelines and the need for comparative clinical trials, result in delayed approvals. In addition, poor domestic production and R&D infrastructure the region lead to import dependency and supply disruptions. Market access issues, such as competition from branded generics, pricing pressures, and patent litigations from originator companies, also constrain growth.

Monoclonal Antibodies: Leading Market Segment

At present, the monoclonal antibodies segment holds almost 55% of the total market share in Middle East and Africa. This leading position is mainly due to their widespread application in the treatment of chronic illnesses such as cancer, rheumatoid arthritis, and various autoimmune disorders. However, the peptide segment is expected to expand at a faster CAGR throughout the forecast period.

Oncological Disorders: Dominating Market Segment

Currently, oncological disorders dominate the Middle East and Africa Biosimilars Market, capturing most the market share. This trend is further supported by an aging population, changes in lifestyle, and improved diagnostic techniques, necessitating affordable treatments, particularly for costly monoclonal antibody therapies. As a result, this presents attractive growth opportunities for biosimilar developers. Additionally, the hematological disorders segment is expected to experience a higher compound annual growth rate (CAGR) during the forecast period.

MIDDLE EAST AND AFRICA BIOSIMILARS MARKET: Key Segments

By Drug Class

Monoclonal Antibodies
Proteins
Peptides
Others

By Therapeutic Area

Oncological Disorders
Autoimmune and Inflammatory Disorders
Hematological Disorders
Metabolic Disorders
Other Disorders

By Type of Manufacturer

Contract Manufacturers
In-house Developers

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Example Players in Middle East and Africa Biosimilars Market

AbbVie
Amgen
Biocon
Celltrion Healthcare
Dr. Reddy's Laboratories
Pfizer
Roche
Samsung Biceps
Sandoz
Teva Pharmaceutical Industries
Viatris

Key Questions Answered in this Report

How many Middle East biosimilars providers are currently engaged in this market?
Which are the leading companies in this market?

Which country dominates the MIDDLE EAST AND AFRICA BIOSIMILARS MARKET?

What are the key trends observed in the MIDDLE EAST AND AFRICA BIOSIMILARS MARKET

What factors are likely to influence the evolution of this market?
What are the primary challenges faced by biosimilars providers in Middle East and Africa?
What is the current and future Middle East and Africa Biosimilars Market size?

What is the CAGR of MIDDLE EAST AND AFRICA BIOSIMILARS MARKET?

How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Complementary Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RAD00007

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Value and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product (GDP)
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Overview of Biologics
6.3. Overview of Biosimilars and Biobetters
6.4. Difference between Innovator Biologics, Biosimilars and Generics
6.5. Advantages of Biosimilars
6.6. Manufacturing of Biosimilars
6.7. Development Timeline of Biosimilars
6.8. Future Perspectives

7. MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Biosimilars: Developers Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters (Region)
- 7.2.4. Analysis by Location of Headquarters (Country)
7.3. Biosimilars: Overall Market Landscape
- 7.3.1. Analysis by Stage of Development
- 7.3.2. Analysis by Therapeutic Area
- 7.3.3. Analysis by Drug Class

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Biosimilars Providers in Middle East and Africa: Company Competitiveness Analysis
- 8.4.1. Small Biosimilar Developers (Peer Group I)
- 8.4.2. Mid-sized Biosimilar Developers (Peer Group II)
- 8.4.3. Large Biosimilar Developers (Peer Group III)
8.5. Capability Benchmarking of top Biosimilar Developers

9. COMPANY PROFILES: MIDDLE EAST AND AFRICA BIOSIMILARS MARKET

9.1. Chapter Overview
9.2. Amgen
- 9.2.1. Company Overview
- 9.2.2. Product Portfolio
- 9.2.3. Financial Information
- 9.2.4. Recent Developments and Future Outlook
9.3. Roche
9.4. Sandoz
9.5. Dr. Reddy's Laboratories
9.6. Teva Pharmaceutical Industries
9.7. Pfizer
9.8. Samsung Bioepis
9.9. Biocon
9.10. Viatris
9.11. Celltrion Healthcare
9.12. AbbVie

10. COST PRICE ANALYSIS

10.1. Chapter Overview
10.2. Factors Contributing to High Price of Novel Biologics
10.3. Pricing of Biosimilars
- 10.3.1. Price Comparison of Different Biosimilars with its Reference Biologic
10.4. Concluding Remarks

11. DEMAND ANALYSIS

11.1. Chapter Overview
11.2. Key Assumptions and Methodology
- 11.2.1. Global Annual Demand for Biosimilars
  - 11.2.1.1. Analysis by Drug Class
  - 11.2.1.2. Analysis by Therapeutic Area
  - 11.2.1.3. Analysis by Type of Manufacturer
  - 11.2.1.4. Analysis by Distribution Channel
  - 11.2.1.5. Analysis by Geographical Regions

12. MARKET IMPACT ANALYSIS

12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion

13. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Middle East and Africa Biosimilars Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
13.4. Roots Analysis Perspective on Market Growth
13.5 Scenario Analysis
- 13.5.1. Conservative Scenario
- 13.5.2. Optimistic Scenario
13.6. Key Market Segmentations

14. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY DRUG CLASS

14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Middle East and Africa Biosimilars Market: Distribution by Drug Class
- 14.3.1. Middle East and Africa Biosimilars Market for Monoclonal Antibodies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 14.3.2. Middle East and Africa Biosimilars Market for Proteins, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 14.3.3. Middle East and Africa Biosimilars Market for Peptides, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 14.3.4. Middle East and Africa Biosimilars Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
14.4. Data Triangulation and Validation

15. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY THERAPEUTIC AREA

15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Middle East and Africa Biosimilars Market: Distribution by Therapeutic Area
- 15.3.1. Middle East and Africa Biosimilars Market for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 15.3.2. Middle East and Africa Biosimilars Market for Autoimmune and Inflammatory Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 15.3.3. Middle East and Africa Biosimilars Market for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 15.3.4. Middle East and Africa Biosimilars Market for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 15.3.5. Middle East and Africa Biosimilars Market for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
15.4. Data Triangulation and Validation

16. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY TYPE OF MANUFACTURER

16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Middle East and Africa Biosimilars Market: Distribution by Type of Manufacturer
- 16.3.1. Middle East and Africa Biosimilars Market for Contract Manufacturers, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 16.3.2. Middle East and Africa Biosimilars Market for In-house Developers, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
16.4. Data Triangulation and Validation

17. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL

17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Middle East and Africa Biosimilars Market: Distribution by Distribution Channel
- 17.3.1. Middle East and Africa Biosimilars Market for Hospital Pharmacies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 17.3.2. Middle East and Africa Biosimilars Market for Retail Pharmacies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
- 17.3.3. Middle East and Africa Biosimilars Market for Online Pharmacies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation